Background Stroke is common during the first few weeks after a transient ischemic attack
(TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may …

Background—The Clopidogrel in High-risk patients with Acute Non-disabling
Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel …

Importance Results show the short-term risk of hemorrhage in treating patients with acute
transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus …

Background: In patients with acute minor ischemic stroke or high-risk transient ischemic
attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic …

Background Combination antiplatelet therapy with clopidogrel and aspirin may reduce the
rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient …

Importance Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary
prevention after minor ischemic stroke or transient ischemic attack (TIA). Uncertainties …

BACKGROUND: Acute nondisabling cerebrovascular events are common and often portend
a disabling stroke. Aspirin is the only antiplatelet agent to have been studied in patients …

Background The Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilisation,
Management and Avoidance (CHARISMA) trial reported no statistically significant benefit of …

Background Clopidogrel was superior to aspirin in patients with previous manifestations of
atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high …

Objective To assess the effectiveness and safety of dual agent antiplatelet therapy
combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events …